

Preeclampsia

Dr Rowdha Almansoob

HYPERTENSION IN PREGNANCY

- ❖ Diastolic BP \geq 110 mmHg on any one occasion
- ❖ or diastolic BP \geq 90 mmHg on 2 or more consecutive occasions \geq 4 h apart, not measured during labour.
- ❖ Mild $>$ 140/90
- ❖ Moderate $>$ 150/100
- ❖ Severe $>$ 160/110

BLOOD PRESSURE MEASUREMENT

- ❖ Use of the mercury sphygmomanometer - the gold standard
- ❖ measured with the woman seated/ feet supported or on the ground/
the arm at the level of the heart
- ❖ Appropriate cuff/ KORATKOFF V for measuring Diastolic pressure

HYPERTENSION IN PREGNANCY

Chronic Hypertension

- ❖ Known Hypertensive or Hypertension presenting before 20th weeks of gestation
- ❖ Hypertension diagnosed after 20th week not normalising after 12 weeks post partum
- ❖ complicates 3-5% of pregnancies and doubles the risk of preeclampsia.

Gestational Hypertension (Pregnancy Induced Hypertension)

- ❖ New hypertension presenting after 20 weeks gestation without significant proteinuria
- ❖ resolves within 6 weeks of delivery.
- ❖ occurs in 6-7% of pregnancies
- ❖ 15-25% - develop pre-eclampsia.
- ❖ tends to recur in subsequent pregnancies

PREECLAMPSIA

- ❖ a multisystem disorder
- ❖ occurring after the 20th week of pregnancy
- ❖ with variable features, severity and rate of progress
- ❖ occurs in 2–3% of all pregnancies
- ❖ increase in morbidity and mortality for both mother and child

SUPERIMPOSED PREECLAMPSIA

❖ New onset proteinuria after 20th week of gestation in a patient with chronic hypertension

PREECLAMPSIA

- ❖ Risk factors

- Maternal
- Paternal

❖ **Maternal causes**

- **Inherent**

- * **Genetic predisposition**
- * **Extremes of age**
- * **Nulliparity**
- * **Prior or family history of Preeclampsia or cardiovascular disease**
- * **woman born small for gestational age**
- * **Afro-carribean origin**

Maternal causes

- Medical conditions

- * Chronic Hypertension
- * Diabetes Mellitus(Type 1 or Gestational)
- * Chronic renal disease
- * Connective tissue disorders
- * Stress
- { Smoking???)

Maternal causes

- Pregnancy specific
 - * Multiple gestation
 - * New partner
 - * H mole/ Hydrops fetalis
 - * Fetal structural anomalies
 - * Oocyte donations
 - * UTI

Paternal causes

- A partner who fathered a pre-eclamptic mother previously

A first time father

- Barrier contraception

Donor insemination

AETIOLOGY

- precise aetiology still unknown (DISEASE OF THEORIES)
- Ancient Greeks (WONDERING WOMB)

CURRENT THEORIES

- ❖ genetic predisposition
- ❖ an autoimmune reaction against the placenta

PATHOPHYSIOLOGY




Fig. 1 Invasion defects in pre-eclampsia. (A) In a normal placenta, extravillous cytotrophoblast (ECTB) cells (green) move into the decidua (endometrium) and myometrium via interstitial invasion. Some ECTB cells enter maternal spiral arteries and replace the endothelial cells of the vessel walls, becoming endovascular ECTB (eECTB) cells, increasing vessel compliance and maximizing blood flow into placental blood spaces. (B) In the placenta of a preeclamptic patient, interstitial invasion is shallow and limited, with many ECTB cells in the basal plate remaining attached to anchoring villi (AV). Endovascular invasion is nearly absent, and spiral arterioles remain 'stiff'. FV, floating villi. Image courtesy of The Curators of the University of Missouri. 2011), a public corporation.

Deficient placental implantation and platelet aggregation within
the placental bed



placental ischaemia and release of Vasoactive substances



widespread endothelial damage and Platelet adherence/
Increased vascular permeability



profound vasospasm with multisystem effects

❖ Prostaglandin metabolism is also disordered

❖ Increase in thromboxane and a decrease in prostacyclin concentrations

❖ leading to platelet dysfunction and further vasoconstriction

SYSTEMIC EFFECTS OF PREECLAMPSIA

Maternal

CVS

- ❖ Widespread vasoconstriction
- ❖ Normal or increased systemic vascular resistance
- ❖ Left ventricular failure
- ❖ Increased vascular permeability and oedema
- ❖ Decreased circulating blood volume

CENTRAL NERVOUS SYSTEM

- ❖ Headaches
- ❖ Visual disturbances
- ❖ Hyper-reflexia
- ❖ Cerebral haemorrhage
- ❖ Convulsions

RENAL INVOLVEMENT

- ❖ Reduced GFR
- ❖ Reduced urea clearance and increased uric acid concentrations
(BU > 6.0 mg/dl associated with pre-eclampsia)
- ❖ Proteinuria and hypoproteinaemia
(total protein excretion \geq 300 mg per 24 h/
2 specimens of urine collected \geq 4 h apart with \geq 2+ on the protein reagent strip)
- ❖ Oliguria
- ❖ Acute renal failure

RESPIRATORY SYSTEM

- ❖ Pulmonary oedema
- ❖ Facial and laryngeal oedema
- ❖ Adult respiratory distress syndrome

LIVER

- ❖ Abnormal liver function tests
- ❖ Subcapsular haemorrhage and epigastric pain
- ❖ Liver rupture

COAGULATION

- ❖ Increased turnover of fibrinogen, fibrin and platelets
- ❖ Thrombocytopaenia
- ❖ Impaired platelet function
- ❖ DIC
- ❖ HELLP syndrome (haemolysis, elevated liver enzymes, low platelets)

FETAL

- ❖ Decreased placental perfusion
- ❖ Placental ischaemia and infarction
- ❖ IUGR
- ❖ Placental abruption
- ❖ Preterm labour

SEVERE PREECLAMPSIA



❖ any one of the following occurring after the 20th week of pregnancy

- (i) severe hypertension (SBP > 160 mmHg or DBP > 110 mmHg)
- (ii) proteinuria > 5 g per 24 h
- (iii) oliguria < 400 ml per 24 h
- (iv) cerebral irritability
- (v) epigastric or right upper quadrant pain (liver capsule distension)
- (vi) pulmonary oedema

ECLAMPSIA

- ❖ occurrence of convulsions in a woman with pre-eclampsia (with no other attributable cause)
- ❖ 1 in 2000 deliveries in the industrialised world
- ❖ Cerebral vasoconstriction/ ischaemia/ vasogenic oedema
- ❖ Incidence ante-partum (40%)/intra-partum (20%) / post-partum (40%)
- ❖ Severe preeclampsies are at a higher risk
- ❖ risk not increased with higher BP

HELLP SYNDROME

- ❖ Haemolysis, elevated liver enzymes and low platelet count
- ❖ occur with severe pre-eclampsia
- ❖ hepatic ischaemia with periportal haemorrhage and necrosis
- ❖ Partial HELLP - only 1 or 2 of the criteria are present

HELLP SYNDROME

5-6

- ❖ may occur when hypertension or proteinuria is absent or minimal
- ❖ 20% of cases - post-partum
- ❖ may be asymptomatic
- ❖ may present with epigastric/right hypochondrial pain, malaise, N & V

HELLP SYNDROME

5-6%

Differential diagnosis

- ❖ acute fatty liver of pregnancy
- ❖ Cholestasis
- ❖ viral hepatitis
- ❖ thrombocytopaenia from other causes(HUS/ TTP)
- ❖ Early haemolysis can be detected by measuring serum haptoglobin concentrations.

HELLP SYNDROME

- ❖ Rapidly worsens for 24–48 h
- ❖ resolves within 6 days
- ❖ Increased maternal and fetal morbidity
- ❖ Increased risk of other complications of preeclampsia

MANAGEMENT OF PRE-ECLAMPSIA

- ❖ Early diagnosis
- ❖ control of blood pressure
- ❖ prevention of convulsions
- ❖ timely delivery

ANTIPLATELET THERAPY

5.3.4

- ❖ Patients with high risk of Preeclampsia
- ❖ 75 mg of aspirin daily from 12 weeks up to 36 weeks
(CLASP TRIAL)

- ❖ Close monitoring with frequent Blood pressure readings
- ❖ Good IV access————— ❖ ❖ ❖
- ❖ CVP guided goal directed fluid therapy
- ❖ Meticulous fluid balance

Ix

- ❖ Full blood count, RFT and LFT
- ❖ If platelet count < 100,000- Other clotting studies

Control of blood pressure

- ❖ Target MAP - 100–140 mmHg (130/90–170/110 mmHg)
- ❖ Anti-hypertensive therapy
- ❖ Avoid sudden drops

ANTIHYPERTENSIVES IN PREECLAMPSIA

❖ **Nifedipine**

Administration

- Use orally or sublingually.
- 10mg nifedipine, repeated after 30 minutes.
- Maintenance dose - 8 hourly, maximum dose - 20mg

❖ *Adverse effects*

- Sublingual use -rapid profound BP
- Use cautiously with MgSO₄ (both antagonise calcium).

LABETALOL

❖ *Administration*

- 5-20mg boluses slowly IV at 10 minute intervals to a maximum of 50mg

- IV infusion 20 mg/hour

Double infusion in 30 minute intervals

- maximum -160 mg/hour

- oral - 200-1600mg in divided doses

- Absorption may be reduced in labour

❖ *Contraindications*

- Asthma and cardiac failure

HYDRALAZINE

❖ *Mode of action*

- Direct acting arterial vasodilator.

❖ *Administration*

- Never infuse hydralazine via the same cannula as magnesium sulphate –avoid using the same arm
- ❖ IV 5mg incremental boluses or 5-20mg/hr infusion
- ❖ Side effects- Headache/ tremors/ vomiting- may mimic eclampsia

METHYL DOPA

- ❖ Centrally acting- reduces sympathetic outflow
- ❖ Dose- 1-3g/day in 3-4 divided doses PO
- ❖ Side effects drowsiness/ depression / postural hypotension

Mg Therapy

5.4.1

- ❖ Not used as an antihypertensive
- ❖ In severe preeclampsia with fx of CNS irritability

FLUID THERAPY

- ❖ Reduced plasma volume of 30-40%
- ❖ IV therapy is often necessary
- ❖ Inverse relationship between intravascular volume and severity of hypertension
- ❖ Volume expansion - reduce SVR and SBP

BLT Risk of pulmonary oedema

- Increased risk of pulmonary oedema

- ❖ low colloid oncotic pressure (Crystalloids causes a further decrease ,
- ❖ left ventricular dysfunction (colloid will increase the CVP)
- ❖ Optimum fluid therapy is difficult to achieve

FLUID THERAPY CID

❖ Crystalloids - 1–2 ml /kg/hr

(Limit maintenance to 80 ml/hr if no ongoing losses

NICE GUIDELINES- 2010)

❖ colloids if CVP and serum albumin are low

❖ Blood and blood products as necessary

❖ Oliguria - treated with a fluid challenge of 250 ml of crystalloid

❖ CVP monitoring If there is no response

❖ Target CVP - 3–5 mmHg and a UOP> 0.5ml /kg/hr

DELIVERY

- ❖ close collaboration of obstetric, paediatric and anaesthetic teams
- ❖ Adequate optimisation prior to delivery- blood pressure control / adequate fluid resuscitation
- ❖ Supine hypotension avoided by 15° lateral displacement
- ❖ Prolong labour > 32 weeks till fetal lung maturity/ place of IM steroids

LABOUR

Epidural analgesia -preferred choice for labour

- ❖ controlling of blood pressure
- ❖ improving placental perfusion due to vasodilatation
- ❖ reduces the stress response and release of catecholamines which occurs with pain.



Money If you stop choosing me I can
let the nurse know we want that epidural

EPIDURAL ANALGESIA FOR LABOUR

- ❖ A platelet count $< 50,000$ - absolute contraindication
- ❖ Platelet count of 50-100,000 acceptable if rest of coagulation screen is normal
- ❖ BT gives a better indication of platelet function (significant operator variability)
- ❖ TEG if available
- ❖ Fluid preloading may precipitate pulmonary oedema

ANAESTHESIA FOR C-SECTION

- ❖ Regional anaesthesia - the preferred choice
- ❖ epinephrine in epidural mixtures - avoided
- ❖ fentanyl improve the sensory component of the block
- ❖ altered pharmacokinetics of lidocaine (*e.g.* reduced drug clearance)
- ❖ Bupivacaine or ropivacaine - better

- ❖ severity of hypotension similar in spinal or epidural
- ❖ uteroplacental perfusion not reduced may increase
- ❖ Spinals or CSE techniques increasingly used

Hypotension after regional techniques

- ❖ treated with a combination of crystalloid, colloid and ephedrine(risk of pulmonary oedema)
- ❖ Sensitivity to vasopressors increased
- ❖ ephedrine - administered cautiously in low doses
- ❖ Phenylephrine alternative

GENERAL ANAESTHESIA

- ❖ Emergency Caesarean sections
- ❖ failed regional techniques
- ❖ regional techniques are contra indicated
- ❖ Post-ictal patient with low GCS
- ❖ patients with recurrent seizures
- ❖ Presence of pulmonary oedema associated with hypoxia

- ❖ Airway assessment (air way oedema)
- ❖ Possible difficult intubation
- ❖ Awake intubation – safest approach
- ❖ Nasal/ oral intubation – risk of significant bleeding (venous engorgement, disordered coagulation)
- ❖ Exaggerated Intubation response

GENERAL ANAESTHESIA

❖ Drugs used to obtund the hypertensive response to laryngoscopy and intubation

magnesium sulphate 40 mg kg⁻¹

- Short acting opioids (e.g. alfentanil 10 µg kg⁻¹)
- β-blockers (e.g. esmolol 0.5 mg kg⁻¹ or labetalol 10–20 mg)
- lidocaine (1.5 mg kg⁻¹ given 5 min prior to intubation)



- ❖ Maintenance- Isoflurane better
- ❖ Continuous monitoring hemodynamic/ respiratory parameters+ Fluid balance
- ❖ Extubation - an exaggerated cardiovascular response
- ❖ Esmolol or lidocaine
- ❖ Magnesium/Ca²⁺ - prolong the effects of depolarising and NDMB / reduce fasciculations with succinylcholine
- ❖ Nerve stimulators - used in all cases
- ❖ Laryngeal oedema may worsen during surgery
- ❖ ETT cuff - deflated to ensure cuff leak prior to extubation

REASONS FOR PROLONGED RECOVERY AFTER GA

- ❖ Effect of excess anaesthetic agents
- ❖ Effect of excess opiates
- ❖ Inadequate reversal of neuromuscular block: magnesium potentiates NDMB'S
- ❖ Respiratory depression due to magnesium toxicity
- ❖ Hypoglycaemia
- ❖ intracranial event

USE OF OXYTOCIC AGENTS

- ❖ Syntocinon- drug of choice
- ❖ Ergometrine to be avoided
- ❖ Prostaglandin analogues(PDF 2nd)
 - risk of aggravation of hypertension

POST-DELIVERY

- ❖ pre-eclampsia may worsen after delivery/up to 30% of cases- only diagnosed post-partum
- ❖ HDU/ ICU care with close observation
- ❖ control of blood pressure
- ❖ Meticulous fluid balance- Fluid overload avoided
- ❖ Use of invasive monitoring if necessary

❖ Anti-hypertensive treatment should be continued as long as is necessary

❖ Good analgesia to reduce the stress response caused by uncontrolled pain

- Epidural

- Opioids (PCA)

- Paracetamol(CAUTION IN LIVER IMPAIREMENT)

- NSAIDS (RISK OF BLEEDING IN COAGULOPATHY/ RENAL INSUFFICIENCY)

❖ **Thromboprophylaxis**

- To be considered in all cases

ECLAMPSIA

- ❖ severity of hypertension does not correlate well with the incidence of convulsions
- ❖ Seizures are generalised and often self limiting
- ❖ Magnesium sulphate - Treatment of choice for the convulsions
prevention of recurrent fits

ECLAMPSIA MX

❖ Goals

Cessation of seizures

Stabilisation of A, B and C

- Prevention of further seizures
- Prevention of damage to and safe delivery of the foetus

❖ The Magnesium Sulphate for Prevention of Eclampsia (MAGPIE) Trial- 2002

(women with pre-eclampsia treated with magnesium sulphate had a 58% lower risk of eclampsia and a lower mortality rate compared to the placebo group)

❖ Mg therapy has also been found to be effective in reducing Intubation, pneumonia and ICU admissions

MAGNESIUM THERAPY

- ❖ Exact mechanism of action is not known
- Antagonist at calcium channels reducing systemic and cerebral vasospasm

NMDA receptor antagonist anticonvulsant action

- Increased production of endothelial prostacyclin may restore thromboxane-prostacyclin imbalance
- ❖ Close monitoring of oxygen saturation and patellar tendon reflexes (hourly) is necessary
- ❖ Magnesium crosses the placenta (neonatal hypotonia and respiratory depression)

REGIMENS OF MgSO_4 THERAPY

❖ Collaborative Eclampsia Trial regimen- 1995

(A loading dose of 4 g is given over 5–10 min, followed by an infusion of 1 g h⁻¹ for 24 hours post delivery or last seizure whatever comes later

recurrent seizures - additional 2 g IV MgSO_4)

❖ ultra-short protocol of magnesium sulphate (found to be effective in 92.6% eclamptic patients)

(MgSO_4 4 g IV followed by 10 g IM)

MAGNESIUM TOXICITY

5 ★ 1

	mmol litre ⁻¹
Normal plasma level (NB most magnesium is intracellular)	1
Therapeutic range	2 – 3
ECG changes	3 – 5
Loss of deep tendon reflexes	5
Muscle paralysis, Respiratory depression	6 – 7.5
Cardiac arrest	12

ECLAMPSIA MANAGEMENT....

- ❖ Phenytoin and diazepam have been widely used in the past-replaced by magnesium
- ❖ Any further treatment of seizures is supportive (*e.g.* intubation and ventilation)

MX OF SPECIFIC COMPLICATIONS

❖ Management of acute pulmonary oedema

- 2.9% of pre-eclamptics (30% of cases antepartum)

- stabilisation of the mother

- SpO2 monitoring

oxygen supplementation either via NIV devices / intubation and ventilation

IV furosemide bolus 20- 40 mg over 2 min

repeated doses of 40-60 mg after approximately 30 min.

- maximum dose 120 mg h.

- IV morphine 2–5 mg
- fluid restriction and strict fluid balance
positioning (head elevated)
- uterine displacement

Management of oliguria in post partum

- ❖ normal renal and respiratory function requires no treatment
- ❖ use of furosemide or low-dose dopamine with normal RFT's-
NOT RECOMMENDED
- ❖ Spontaneous diuresis occur after 24-48 hrs of delivery

Management of acute renal decompensation

Indications for haemodialysis

- persistent acidaemia
- hyperkalaemia
- volume overload
- Uraemia

Intensive care management

NEW DEVELOPMENTS

❖ Ketanserin

Increased serotonin levels in preeclampsia

Serotonin 1 receptors in endothelial cells- Increased NO release

- Serotonin 2 receptor activation- Increased platelet activation and vasoconstriction

As endothelial cells are damaged in preeclampsia prominent action on 5-2 receptors

selective serotonin-2-receptor antagonist/ some antagonistic effects at $\alpha 1$ adrenoreceptors at high doses reduced BP

PAST QUESTIONS

❖ 1993 MID Anaesthesiology/ Essay

2) Outline the clinical fx of Preeclampsia

Discuss the special problems in the administration of anaesthesia to a patient with severe preeclampsia

❖ 1995 MID Anaesthesiology/ Essay

3) Discuss pre, intra and postop Mx of a patient with severe Preeclamptic toxemia in the 36th week of Pregnancy

❖ 1999 M.D. Anaesthesiology/ Essay

2) A patient is admitted to labour ward at 36 weeks of gestation with foetal distress and severe preclampsia. She needs an emergency c-section. How would you manage this patient?

5*4


❖ 2000 MD Anaesthesiology/ SAQ

9) What are the therapeutic effects and side effects of magnesium sulphate therapy in pre-eclampsia?

How would you treat any toxicity that occur?


❖ 2006 MD Anaesthesiology / SAQ

11) What are the principles of Mx of Eclampsia?



❖ 2007 MD Anaesthesiology/ Essay

1.) Discuss the perioperative Mx of a lady who is 36 weeks pregnant with Preeclampsia who requires C-section.



❖ 2012 MD Anaesthesiology/ SAQ

- A 28 year old primigravida at 30 weeks' gestation is brought to the emergency department with a history of a headache and repeated fits. On examination, her BP is 170/110, heart rate 100/min, GCS 12/15. Her platelet count is 30,000/mm³ and INR 1.9

- A. What is the immediate management?
- B. How would you prepare this patient for an emergency c-section?
- C. Describe your anaesthetic technique of choice?

REFERENCES

- ❖ The diagnosis and management of pre-eclampsia , Elaine Hart /Sue Coley
British Journal of Anaesthesia | CEPD Reviews | Volume 3 Number 2 2003
- ❖ Recent advances in management of Preeclampsia. Pallab Rudra, Sonela
Basak /British Journal of Medical practitioners -2013, september
- ❖ Hypertension in pregnancy: NICE GUIDELINES-diagnosis and
management-25 August 2010
- ❖ ATOW- Preeclampsia-2005/05
- ❖ Morgan & Mikhailis- 6th edition
- ❖ The management of severe preeclampsia/eclampsia. Royal College of
Obstetricians and Gynaecologists. Guideline no.10a-2006

THANK
YOU!

